Theralase Technologies Inc. has announced an optimization to the delivery schedule of its proprietary anti-cancer vaccine, increasing its efficacy in the destruction of brain cancer. The anti-cancer vaccine was evaluated in a rat glioma ("RG2") animal model, an established model of Glioblastoma Multiforme ("GBM"), a deadly form of human brain cancer. As originally disclosed, the anti-cancer vaccine was created by exposing RG2 cells to patented stressors extracorporeally (outside the body) and then injecting this anti-cancer vaccine into rats to delay the progression of brain glioma tumours.